26
|
Abstract
A filterable agent was isolated from the blood and from washings of the upper respiratory passages of a young laboratory worker during a mild, acute, febrile illness. This agent was identified as a strain of Venezuelan equine encephalomyelitis virus. Circulating specific complement-fixing and neutralizing antibodies not present in sera withdrawn during the acute phase of illness were demonstrated in sera obtained during convalescence. A fellow laboratory worker who became similarly ill simultaneously also developed during convalescence specific circulating antibodies not present prior to illness.
Collapse
|
27
|
Casals J, Palacios R. THE COMPLEMENT FIXATION TEST IN THE DIAGNOSIS OF VIRUS INFECTIONS OF THE CENTRAL NERVOUS SYSTEM. ACTA ACUST UNITED AC 2010; 74:409-26. [PMID: 19871144 PMCID: PMC2135201 DOI: 10.1084/jem.74.5.409] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
A specific complement fixation test can be obtained in various central nervous system virus infections by using as antigens emulsions of infected brain tissue, freezing and thawing the brain emulsion, and then centrifuging it in an angle head centrifuge at 3500 R.P.M. for 1 hour. The method has proved reliable in the case of rabies, St. Louis encephalitis, Japanese B encephalitis, lymphocytic choriomeningitis, Eastern equine encephalomyelitis, Western equine encephalomyelitis, louping ill, and spontaneous encephalomyelitis of mice (Theiler's disease). The specificity of the reaction, regardless of the virus involved, requires different temperatures of inactivation of the sera according to animal species: 56°C. for guinea pig, 60°C. for mouse, and 65°C. for rabbit and dog sera, all heated for 20 minutes. For human sera a temperature of inactivation of 60°C. also for 20 minutes has been adopted; at this temperature the reaction is in general specific. Complement-fixing antibodies in high titre were found in the sera of rabbits, guinea pigs, mice, and dogs immunized with rabies virus. Complement-fixing antibodies were present in high titre in sera drawn from two persons 8 years after an attack of louping ill, from five persons 2½ years after an attack of Eastern equine encephalomyelitis, and from two persons 2½ years after Western equine encephalomyelitis. In cases of St. Louis encephalitis and lymphocytic choriomeningitis, complement-fixing antibodies have been found shortly following infection but not after long periods.
Collapse
|
28
|
Abstract
1. W-Swiss mice 60 or more days old are more readily immunizable against rabies virus infection than 20 day old or younger mice; this difference in immunizability with increasing age is most conspicuous when vaccination with virulent virus is followed by intracerebral test infection and least apparent when vaccination with avirulent virus is followed by intramuscular test infection. 2. The titre of circulating neutralizing antibodies does not parallel the titre of immunity.
Collapse
|
29
|
Webster LT, Casals J. THE QUANTITY OF IRRADIATED NON-VIRULENT RABIES VIRUS REQUIRED TO IMMUNIZE MICE AND DOGS. ACTA ACUST UNITED AC 2010; 73:601-15. [PMID: 19871099 PMCID: PMC2135151 DOI: 10.1084/jem.73.5.601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
In the experiments described above, we found with respect to tissue culture rabies virus that 1 cc., which contains approximately 50,000 mouse intracerebral lethal doses, properly irradiated, was required to immunize a mouse; 500 cc., which contain 25,000,000 doses, were required to immunize a 20 pound beagle dog. Tissue culture virus concentrated ten times proved capable of immunizing mice in a dose one-tenth as large as that required for unconcentrated culture virus. Brain virus suspensions were centrifuged so as to remove a large part of the tissue particles without striking loss in the virulence of the supernatant. The centrifuged supernatants of 1 to 5 per cent brain virus suspensions were irradiated so as to destroy virulence and yet retain immunizing potency. Irradiated supernatants of mouse brain virus proved capable of immunizing mice as well as or better than similar supernatants treated with chloroform. 0.1 cc. of a 1 per cent irradiated dog brain virus containing approximately 50,000 mouse intracerebral lethal doses immunized mice effectively.
Collapse
|
30
|
Webster LT, Casals J. A NON-VIRULENT, SINGLE-DOSE RABIES VACCINE FOR PROPHYLACTIC IMMUNIZATION OF DOGS. ACTA ACUST UNITED AC 2010; 76:185-94. [PMID: 19871228 PMCID: PMC2135227 DOI: 10.1084/jem.76.2.185] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Our studies on rabies vaccines thus far have led us to the view that in order to develop and test vaccines, quantitative methods are necessary, and that such quantitative methods may be exploited to greatest advantage by using mice, preferably W-Swiss, as the test animal. Dogs, due to their variability and susceptibility to intercurrent infections when kept under experimental conditions, are useful chiefly to check whether or not a vaccine produces a high grade of immunity; they remain of limited value in testing the comparative potencies of weak vaccines. A second point is that the Pasteur strain of virus has proved as potent as any tested for the preparation of vaccines. Another point is that virus material for preparing vaccines must titre at least 330,000 mouse doses per cc. to be effective. This requirement has eliminated all culture vaccines thus far reported, with the possible exception of Plotz's (7) and leaves virus-containing brain tissue as the sole potent source of vaccine. In summary, we believe that a single injection of non-virulent irradiated vaccine, prepared as herein described, immunizes mice and dogs effectively against a subsequent test inoculation of virulent rabies virus and does so to a greater degree than do other vaccines now obtainable. It is easily and quickly prepared, keeps well, and has a low nitrogen content.
Collapse
|
31
|
Casals J, Webster LT. RELATIONSHIP OF THE VIRUS OF LOUPING ILL IN SHEEP AND THE VIRUS OF RUSSIAN SPRING-SUMMER ENCEPHALITIS IN MAN. ACTA ACUST UNITED AC 2010; 79:45-63. [PMID: 19871352 PMCID: PMC2135430 DOI: 10.1084/jem.79.1.45] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
An experimental study of three strains of Russian spring-summer encephalitis virus and one of louping ill virus has yielded the following results:— 1. The sera of mice hyperimmunized to the viruses of Russian encephalitis and louping ill respectively have produced complement fixation with both antigens in almost precisely the same titer. 2. In neutralization tests hyperimmune sera against the Russian virus strains protected against louping ill virus to the same extent as against the Russian virus strains. Conversely, hyperimmune sera against the louping ill virus protected against the Russian viruses, although to a less degree than against louping ill virus. 3. In cross-resistance tests in mice, a vaccine consisting of formolized Russian virus gave strong protection against this latter and moderate protection against louping ill virus. Formolized louping ill virus gave moderate protection against infection with louping ill and considerably less against the Russian virus. 4. Serum from an individual recovered from a laboratory infection with louping ill virus contracted in 1933 gave positive complement fixation and neutralization tests with the Russian spring-summer encephalitis, as well as with louping ill virus. 5. Serum from a patient who became infected with either Russian or louping ill virus or both while working with the viruses in the laboratory in the fall of 1942, gave positive reactions on complement fixation and neutralization tests against them both. 6. No such similarities have been found with other central nervous system viruses. Hence it would appear that they are specific.
Collapse
|
32
|
Casals J. Diagnosis of Epidemic Encephalitis by Complement-fixation Tests. Am J Public Health Nations Health 2008; 31:1281-4. [PMID: 18015535 DOI: 10.2105/ajph.31.12.1281] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Calvo JF, Garrido L, Eraso A, Mañes A, Casals J. SU-FF-T-14: A Filmless Verification of the Radiation Isocenter for a Micromultileaf-Based Radiosurgery System. Med Phys 2006. [DOI: 10.1118/1.2240920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Calvo J, Eraso A, Garrido L, Casals J. 459 Daily constancy checks of flatness, symmetry and output for photon beams using a commercial electronic portal image device (EPID). Radiother Oncol 2005. [DOI: 10.1016/s0167-8140(05)81435-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Peña J, Solano E, Mendoza A, Casals J, Planell JA, Gil FJ. Effect of the M(s) transformation temperature on the wear behaviour of NiTi shape memory alloys for articular prosthesis. Biomed Mater Eng 2005; 15:289-93. [PMID: 16010037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The main objective of this work has been the characterisation and correlation of the wear behaviour of the NiTi shape memory alloys in their different phases. The weight losses for the different alloys in function of the present phase, and of the M(s) transformation temperature are studied. Adhesive wear tests, Pin-on-Disk, according to the ASTM-G99 standard have been carried out. The thermoelastic martensitic transformations that cause the super-elastic effect, the reorientation and coalescence of martensitic plates and the damping effect promotes a high ability to accommodate large deformations without generating permanent damages that causes the wear. The resulting plastic deformation may be accumulated during wear process without generating fracture. The results show that the wear resistance is mainly dependent of the M(s) transformation temperature for both alloys. For the NiTi alloys also the Ni atomic percentage and the hardness of the alloys are important parameters in the wear behavior.
Collapse
|
36
|
Carrillo-Muñoz AJ, Guglietta A, Palacín C, Casals J, del Valle O, Guardià C, Rodríguez V, Quindós G. In vitro Antifungal Activity of Sertaconazole Compared with Nine Other Drugs against 250 Clinical Isolates of Dermatophytes and Scopulariopsis brevicaulis. Chemotherapy 2004; 50:308-13. [PMID: 15608448 DOI: 10.1159/000082631] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2004] [Accepted: 07/13/2004] [Indexed: 11/19/2022]
Abstract
We have tested 250 strains belonging to 15 species of clinically important dermatophytes and Scopulariopsis against ten antifungal drugs using an agar diffusion method (NeoSensitabstrade mark, Rosco, Taastrup, Denmark). Some of the experimental factors were adapted to dermatophyte development, such as temperature (28 vs. 35 degrees C) and time of incubation (2-5 days vs. 21-74 h). The antifungals used are itraconazole, ketoconazole, miconazole, clotrimazole, sertaconazole, terbinafine, tioconazole, fluconazole, isoconazole and econazole. Except for fluconazole, all the drugs tested have shown to be highly effective, especially sertaconazole and terbinafine. Percentages of susceptibility ranged between 94% for terbinafine, 87.6% for sertaconazole and 86.4% clotrimazole; 81.6% econazole; 42.8% fluconazole; 57.2% isoconazole; 78.4% itraconazole; 74.4% ketoconazole; 73.3% miconazole, and 85.2% for tioconazole. Percentages of resistance were similar between sertaconazole and terbinafine (4%) but in contrast to the 48% obtained for fluconazole.
Collapse
|
37
|
Tebeu PM, Popowski GY, Verkooijen HM, Casals J, Lüdicke F, Zeciri G, Usel M, Bouchardy C, Major AL. Impact of peritoneal cytology on survival of endometrial cancer patients treated with surgery and radiotherapy. Br J Cancer 2004; 89:2023-6. [PMID: 14647132 PMCID: PMC2376850 DOI: 10.1038/sj.bjc.6601446] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Stage IIIA endometrial cancer includes patients with serosal or adnexal invasion and patients with positive peritoneal cytology only. In this study, we assessed the impact of peritoneal cytology on endometrial cancer survival. All endometrial cancer patients receiving surgery and radiotherapy at the Geneva University Hospitals between 1980 and 1993 were included. Stage lllA cancers were categorised into ‘cytological’ stage lllA (only positive peritoneal cytology) and ‘histological’ stage lllA (serosal or adnexal infiltration). Survival rates were analysed by Kaplan–Meier method and compared using log-rank test. The prognostic importance of peritoneal cytology was analysed by multivariate regression analysis. This study included 170 endometrial cancers (112 stage I, 17 cytological stage IIIA, 18 histological stage IIIA, 9 stage lllB+). Disease-specific survival of cytological stage IIIA was not different from stage I (94 vs 88% respectively, P=0.5) but better than histological stage IIIA (94 vs 51% respectively, P<0.01). Histological stage IIIA patients were at increased risk to die from cancer compared to stage I patients (HR 2.7, 95% CI 1.0–7.7), while cytological stage IIIA patients were not (HR 0.3, 95% CI 0.3–2.0). Cytological stage lllA endometrial cancer has similar prognosis as stage l and better prognosis than histological stage IIIA. Additional research, definitively separating stage and cytology is warranted.
Collapse
|
38
|
Peña J, Casals J, Gil FJ, Planell JA. Effect of the Mstransformation temperature on the wear behaviour of NiTi and CuZnAl shape memory alloys. ACTA ACUST UNITED AC 2003. [DOI: 10.1051/jp4:20031084] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Abstract
The pandemic of von Economo's disease which began in January 1917 preceded that of influenza of 1918-1919 by more than a year. Though it has been customary to link the two it seems unlikely that the latter was responsible for the former as has been proposed. It has been assumed that von Economo's disease (ED) was caused by a virus; but in fact the etiology is in question as no virus has yet been transmitted to experimental animals or cells in culture. However, the presence of oligoclonal IgG bands in the CSF of suspected cases and the finding of chronic active lesions in the brain tissue at autopsy suggests a viral etiology. Occasional, sporadic presumed cases of the disease have been reported within the last 25 years. Encephalitides due to established neurotropic viruses or to other viruses that may on occasion invade the CNS only rarely produce parkinsonism, and when they do it differs from that seen in ED. The present report reviews the overall concept of a viral etiology of Parkinson's disease with particular reference to von Economo's disease.
Collapse
|
40
|
Rovirosa A, Ordi J, Ascaso C, Casals J, Lejarcegui A, Iglesias J, Estapé J, Biete A. [Prognostic factors in uterine sarcomas: a 21-year retrospective study at the Clinic and Provincial Hospital of Barcelona]. Med Clin (Barc) 1998; 111:172-6. [PMID: 9732833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Uterine sarcomas show low incidence and poor outcome despite the treatment. The prognostic factors for the survival were determined in this study. PATIENTS AND METHODS Thirty-nine females with sarcoma of the uterus have been studied retrospectively from January 1975 to December 1996. They were treated in the Gynecology and Radiation Oncology Departments at Hospital Clínic i Provincial of Barcelona. Thirty-seven patients had surgery, 22 radiotherapy and 4 chemotherapy. The influence on the disease-specific survival, disease-free survival, local relapse disease-free survival and metastasis disease-free survival from the following pronostic factors was studied: age, pathologic subtype, miometrial invasion, mitosis, vascular and lymphatic invasion, tumor size, stage, radiotherapy and local relapse. RESULTS 1) The disease-specific survival at 2 and 5 years was 51.5% and 42.5% respectively, and the disease-free survival at 2 and 5 years was 39%; the incidence of local and distant relapses--was 28 and 33%. 2) The multivariate analysis showed that the overall survival and the disease free survival were affected by the vascular invasion (odds ratio [OR] 12 and 32.6, respectively) and the local failure (OR = 3 and 25.5, respectively); the only factor that affected the local relapse-free survival and metastasis free survival was the III and IV stages (OR = 5.6 in both cases). CONCLUSIONS In uterine sarcomas, the vascular invasion and the local relapse were prognostic factors for overall survival and for disease-free survival. In stages III and IV there was a decrease in the local relapse-free survival and metastasis-free survival. A correlation between vascular invasion and advanced stages was found. The outcome of the uterine sarcomas is poor, local and distant failure being responsible for this bad prognosis.
Collapse
|
41
|
Casas F, Ferrer F, Farrús B, Casals J, Biete A. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer 1997. [PMID: 9338459 DOI: 10.1002/(sici)1097-0142(19971015)80:8%3c1366::aid-cncr2%3e3.3.co;2-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Few studies of patients with esophageal small cell carcinoma (SCC) have been conducted. Choice of treatment remains controversial. METHODS The authors analyzed data on 199 evaluable esophageal SCC patients, selected from among 230 patients found in the literature, and a data extraction form that recorded 11 features was completed. To allow for the evaluation of prognostic factors that influenced survival, the patients were grouped according to limited stage (LS), which was defined as disease confined to the esophagus, or extensive stage (ES), which was defined as disease that had spread beyond locoregional boundaries. Univariate and multivariate analyses were performed. Treatment was categorized as either local or local with systemic; for the ES cases, the categories were defined as treatment versus no treatment. RESULTS The tumor site was described in 178 cases (89%). Mean tumor size was 6.1. Pure SCC was found in 137 cases (68.8%), whereas 62 cases (31.2%) showed mixed SCC; 93 (46.7%) were LS, whereas 95 (47.7%) were ES. In 11 cases (5.5%), the stage was not determined. There was a significant difference in survival between patients with LS and those with ES (P < 0.0001). The median survival was 8 months for patients with LS and 3 months for those with ES. Univariate analysis of LS showed 3 significant prognostic factors: age (for patients age < or =60 years, the median survival was 11 months, whereas for those age >60 years, the median survival was 6 months), tumor size (for those with tumors < or =5 cm, the median survival was 12 months, whereas for those with tumors >5 cm, the median survival was 4 months), and type of treatment (with local plus systemic treatment, the median survival was 20 months, whereas with local it was 5 months). In multivariate analysis, tumor size (P = 0.007) and type of treatment (P < 0.001) were shown to be independent predictive variables. CONCLUSIONS Esophageal SCC is an aggressive type of tumor. This study shows that there are significant differences between LS and ES and that in LS, both tumor size and type of treatment are possible prognostic factors.
Collapse
|
42
|
Casas F, Ferrer F, Farrús B, Casals J, Biete A. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer 1997. [PMID: 9338459 DOI: 10.1002/(sici)1097-0142(19971015)80:8<1366::aid-cncr2>3.0.co;2-d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Few studies of patients with esophageal small cell carcinoma (SCC) have been conducted. Choice of treatment remains controversial. METHODS The authors analyzed data on 199 evaluable esophageal SCC patients, selected from among 230 patients found in the literature, and a data extraction form that recorded 11 features was completed. To allow for the evaluation of prognostic factors that influenced survival, the patients were grouped according to limited stage (LS), which was defined as disease confined to the esophagus, or extensive stage (ES), which was defined as disease that had spread beyond locoregional boundaries. Univariate and multivariate analyses were performed. Treatment was categorized as either local or local with systemic; for the ES cases, the categories were defined as treatment versus no treatment. RESULTS The tumor site was described in 178 cases (89%). Mean tumor size was 6.1. Pure SCC was found in 137 cases (68.8%), whereas 62 cases (31.2%) showed mixed SCC; 93 (46.7%) were LS, whereas 95 (47.7%) were ES. In 11 cases (5.5%), the stage was not determined. There was a significant difference in survival between patients with LS and those with ES (P < 0.0001). The median survival was 8 months for patients with LS and 3 months for those with ES. Univariate analysis of LS showed 3 significant prognostic factors: age (for patients age < or =60 years, the median survival was 11 months, whereas for those age >60 years, the median survival was 6 months), tumor size (for those with tumors < or =5 cm, the median survival was 12 months, whereas for those with tumors >5 cm, the median survival was 4 months), and type of treatment (with local plus systemic treatment, the median survival was 20 months, whereas with local it was 5 months). In multivariate analysis, tumor size (P = 0.007) and type of treatment (P < 0.001) were shown to be independent predictive variables. CONCLUSIONS Esophageal SCC is an aggressive type of tumor. This study shows that there are significant differences between LS and ES and that in LS, both tumor size and type of treatment are possible prognostic factors.
Collapse
|
43
|
Henríquez I, Rovirosa A, Sanchez-Reyes, Güell J, Ayuso J, Casas F, Casals J, Osorlo J, Farrús B, Biete A. Individualized vaginal moulds using 192-lridium and CT evaluation in gynecological (Gyn) tumors. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84964-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Casals J, Rovirosa A, Berenguer J, Sanchez-Reyes A, Pons F, Osorio J, Farrus B, Biete A. 431CT-based simulation to optimize radiotherapy for head and neck cancer in centers without CT simulator and 3D planning systems. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80440-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
45
|
Biete A, Farnís B, Rovirosa A, Casas F, Ferrer F, Conill C, Casals J, Henríquez I, Molla M, Sánchez-Reyes A, Pons F. 771External radiotherapy in Spain: Present and future. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80780-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Casas F, Henriquez I, Casals J, Ferrer F, Rovirosa A, Biete A. 654Radiation therapy morbidity of urological cancer in elderly patients. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80663-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Farrus B, Pons F, Sánchez-Reyes A, de Blas R, Carné N, Arnau O, Rovira M, Casas F, Casals J, Ferrer F, Rovirosa A, Carreras E, Biete A. 488Complementary ribs irradiation by electron beams in total body irradiation. Lung toxicity. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80497-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
48
|
Rovirosa A, Berenguer J, Sánchez-Reyes A, Torres M, Pons P, Casals J, Farros R, Riete A. 578Considerations after simulation by a diagnostic CT of 25 tino vocal cord carcinomas. Quality assurance. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80587-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
49
|
Conill C, Verger E, Alsina M, Güett J, Ferrer F, Casals J, Henriquez I, Biete A. 785 Radiotherapy in the management of cutaneous epidemic Kaposi's sarcoma. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96034-b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Rovirosa A, Ferrer F, Sánchez-Reyes A, Berenger J, Verger E, Ferre J, Guell J, Casals J, Farrús B, Biete A. 205 Quality control in brachytherapy (BT) treatments for head and neck neoplasms. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95462-f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|